Subsequent combined treatment involving low-dose radiotherapy and anti-PD-1 has shown a substantial enhancement in the maturation of TLS within mouse lung adenocarcinoma, leading to a more potent anti-tumor response. Here, PDCD1 is linked to neoplasm.